BioCentury | Aug 1, 2020
Translation in Brief
TScan identifies CD8+ T cell COVID-19 epitopes, plus T3 gears up for Phase I of bacterial cancer therapy, a wearable device to monitor PK and a COVID-19 vaccine
SARS-CoV-2 binding sites for cytotoxic T cells TScan Therapeutics Inc. reported in medRxiv that memory CD8 + T cell responses against SARS-CoV-2 are dominated by a few epitopes in SARS-CoV-2. An analysis of samples from...